Palvella Therapeutics (NASDAQ:PVLA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $38.00 price objective on the stock.

Several other research analysts also recently commented on the stock. TD Cowen assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $16.15 on Tuesday. The stock has a market cap of $181.20 million, a PE ratio of -1.33 and a beta of 0.68. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.

Insiders Place Their Bets

In other news, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the transaction, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.39% of the company’s stock.

Institutional Trading of Palvella Therapeutics

An institutional investor recently bought a new position in Palvella Therapeutics stock. BML Capital Management LLC acquired a new position in Palvella Therapeutics (NASDAQ:PVLA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 42,130 shares of the company’s stock, valued at approximately $506,000. Palvella Therapeutics accounts for 0.3% of BML Capital Management LLC’s holdings, making the stock its 18th biggest position. BML Capital Management LLC owned approximately 0.38% of Palvella Therapeutics at the end of the most recent quarter. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.